This gemeinschaft of care minimizes pregnancy-related risks associated with obesity, such as gestational diabetes and hypertensive disorders
report suspected side effects via the MHRA Yellow Card scheme and contact your GP or NHS 111 if unable to maintain fluid intake
NAC may help support healthy lung function, as well as gastrointestinal health
If you are considering taking Wegovy and lisdexamfetamine (Elvanse) together, or are already prescribed both medications, open communication with your GP or specialist prescriber is essential
Chromium Picolinate 500 by Progressive Labs Introduction: Chromium Picolinate 500 delivers a high-potency dose of chromium along with added support from gamma oryzanol and boron to help maintain healthy blood sugar and metabolic function
Semaglutide Quick Facts: Drug Class: GLP-1 receptor agonist Brand Names: Ozempic (diabetes), Wegovy (weight loss), Rybelsus (oral) FDA Approval: Ozempic approved 2017, Wegovy approved 2021 Manufacturer: Novo Nordisk Dosing: Once weekly injection, starting at 0.25 mg, maximum 2.4 mg Clinical Trial Name: STEP trials (Semaglutide Treatment Effect in People with obesity) Average Weight Loss: 10-15% of body weight over 68 weeks Tirzepatide Quick Facts: Drug Class: Dual GIP/GLP-1 receptor agonist Brand Names: Mounjaro (diabetes), Zepbound (weight loss) FDA Approval: Mounjaro approved 2022, Zepbound approved 2023 Manufacturer: Eli Lilly Dosing: Once weekly injection, starting at 2.5 mg, maximum 15 mg Clinical Trial Name: SURMOUNT trials (Study to evaluate tirzepatide in obesity or overweight) Average Weight Loss: 15-22% of body weight over 72 weeks Primary Difference: The main distinction is that semaglutide activates only GLP-1 receptors, while tirzepatide activates both GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 receptors
